Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said the National Medical Products Administration accepted drug registration applications for two drugs developed by two of its subsidiaries, a Monday bourse filing said.
The NMPA accepted the application of Polymyxin B sulfate for Injection of Guilin Pharmaceutical, while Shanghai Zhaohui Pharmaceutical had its application for Labetalol Hydrochloride Injection accepted by the regulator.
Polymyxin B sulfate for Injection is meant for the treatment of gram-negative bacterial infections while the Labetalol Hydrochloride Injection is for the treatment of severe hypertension.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments